



Doc. 1.

Ministry of Health, Welfare and Sport

> Return address Postbus 20350 2500 EJ Den Haag

Shine Medical Technologies, LLC
Attn Dr. Gregory Piefer
101 E. Milwaukee Street, Suite 600
JANESVILLE, WI 53545
USA

DG Curative Care

Address for visitors:
Parnassusplein 5
2511 VX Den Haag
T 070 340 79 11
F 070 340 78 34
Postbus 20350
2500 EJ Den Haag
www.rijksoverheid.nl

Information

10.2.e.

Date 2 5 JAN. 2021
Subject A warm welcome to SHINE

Our reference
217386

Your reference

*All correspondence addressed
to the postal address quoting
date and reference of this
letter.*

Dear Mr. Piefer,

The Dutch government is very pleased with the interest of SHINE Medical Technologies in the Netherlands for the establishment of its European facilities. The Netherlands has a long lasting history in the research, development and manufacturing of medical isotopes, and we are convinced that SHINE, with its innovative technology, would be an important addition to the Dutch ecosystem in nuclear medicine.

Last year I had the pleasure to meet Mr. Eric Schutt and Mr. Harrie Buurlage and hear about the plans of SHINE Medical Technologies. This has convinced me of the great potential SHINE provides for the future of nuclear medicine.

You have informed me that SHINE plans to open a second production site on this side of the Atlantic. We are proud that, after an extensive search, you have selected the province of Groningen as one of two main contenders for the European location. We have been informed about the constructive cooperation between Groningen and your team and can assure you that the Groningen region is an excellent choice!

The addition of SHINE to the Dutch nuclear medicine landscape would yield new opportunities for collaboration and would make the Dutch nuclear knowledge-infrastructure one of the strongest in the world. This is not only profitable for patients, here and elsewhere, but also from a business perspective for both SHINE and the Netherlands. In this respect, I would also like to point out that a location in the Netherlands entails unrestricted access to the European market. I view SHINE as an important and very promising innovator in the field of medical radio-isotopes and therefore truly believe that SHINE and Groningen would make a great match.

In our conversations you underlined your concern about a level playing field for SHINE and emphasized your request for a guarantee that the Dutch government is committed to this principle. I can wholeheartedly confirm that we as government will be fully compliant to this, both by choice and by legal obligation.



As stated in my letter to parliament of 9 December 2020, I want to make sure that SHINE will have equal opportunities, which is in line with a motion unanimously adopted by the House of Representatives on 27 October 2020, requesting to ensure a level playing field for your company.

Directoraat Generaal
Curatieve Zorg
Directie Geneesmiddelen en Med.
Technologie
Team B

Furthermore, Dutch legislation guarantees that unfair competition cannot take place between companies financed by the government and private market parties. The Competition Act and the associated Market and Government Decree sets rules to ensure that governments and companies controlled by the government do not disrupt the market. The Netherlands is also committed to upholding EU competition rules that guide the internal market. The principle of a genuine level playing field is central to this. This means that enterprises that are active on the European internal market have to comply with competition rules which are enforced by national and European authorities. It also means that the Dutch authorities have to comply to the State aid rules and regulations of the European Treaties and the European Commission.

Specifically in the field of nuclear medicine, the Netherlands complies to the principles set forth in the policy approach released in June 2011 by the High-Level Group on the Security of Supply of Medical Radioisotopes (the HLG-MR principles) to ensure the long-term secure supply of medical radioisotopes, which were formally endorsed by the Organization for Economic Co-operation and Development's (OECD) Steering Committee for Nuclear Energy on 28 April 2011. I hope that these guarantees will earn your trust for opting for the Netherlands for SHINE's European facility.

As you know, I am looking for possibilities to grant a loan to SHINE, and invite you to discuss with us the conditions on which both SHINE and the Ministry can agree. I am currently exploring the possibilities of a joint effort with the Investment & Development Agency for the Northern Netherlands (NOM) and the Province of Groningen who have already committed to a support of 10 million euros. I hope that this is testament to our trust in the potential of SHINE. Furthermore, I would like to offer the assistance of the Ministry of Health, Welfare and Sports when contacting local or regional governmental bodies or agencies. The Ministry is looking forward to further discussing with SHINE Medical Technologies how these aspects can be realized.

To conclude, on behalf of the Netherlands and Groningen I want to express a genuine warm welcome to SHINE and I hope that this letter will help you in making the best choice.

Yours sincerely,


T. van Ark
Minister for Medical Care and Sport